The Influence of CYP2C19 Genetic Polymorphism on the Pharmacokinetics/-Pharmacodynamics of Proton Pump Inhibitor-Containing Helicobacter pylori Treatments

被引：25
|
作者：
Serrano, Dolores [1 ]
Torrado, Susana [1 ]
Torrado-Santiago, Santiago [1 ]
Gisbert, Javier P. [2 ]
机构：
[1] Univ Complutense, Fac Farm, Dept Pharmaceut Technol, E-28040 Madrid, Spain
[2] Hosp Univ La Princesa, Inst Invest Sanitaria Princesa IP, Dept Gastroenterol, Madrid, Spain
来源：
CURRENT DRUG METABOLISM | 2012年 / 13卷 / 09期
关键词：
CYP2C19; genetic polymorphism; Helicobacter pylori eradication; proton pump inhibitor; rabeprazole; omeprazole; lansoprazole; pantoprazole; esomeprazole; CYTOCHROME-P450; ENZYMES; 2C9; 1-WEEK TRIPLE THERAPY; RANDOMIZED OPEN TRIAL; ERADICATION RATE; CURE RATES; OMEPRAZOLE METABOLISM; GENOTYPIC DIFFERENCES; DRUG-METABOLISM; DUAL THERAPY; RABEPRAZOLE;
D O I：
10.2174/138920012803341393
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Proton pump inhibitors (PPIs) are the most potent acid suppressants available. PPIs undergo hepatic metabolism via the CYP2C system for the isoforms CYP2C19 and CYP3A4 in particular. Genetic polymorphisms in CYP2C19 may affect the metabolism of individual PPIs to different extents. Although PPIs are highly effective as a class, differences in their pharmacokinetics, such as bioavailability and metabolism, may translate into differences in clinical outcomes. In Helicobacter pylori infection, a significantly lower eradication rate was seen in extensive metabolizers with omeprazole but no with rabeprazole.
引用
收藏
页码：1303 / 1312
页数：10
相关论文
共 50 条
  • [1] Effect of CYP2C19 Genetic Polymorphism on Pharmacokinetics and Pharmacodynamics of a New Proton Pump Inhibitor, Ilaprazole
    Cho, Hoon
    Choi, Min-Koo
    Cho, Doo-Yeon
    Yeo, Chang-Woo
    Jeong, Hye-Eun
    Shon, Ji-Hong
    Lee, Jun-Yeoun
    Shin, Jae-Soo
    Cho, Mong
    Kim, Dong-Yeon
    Shin, Jae-Gook
    JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 52 (07): : 976 - 984
  • [2] CYP2C19 genotypes in the pharmacokinetics/pharmacodynamics of proton pump inhibitor-based therapy of Helicobacter pylori infection
    Yang, Jyh-Chin
    Lin, Chun-Jung
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2010, 6 (01) : 29 - 41
  • [3] Impact of the CYP2C19*17 Polymorphism on the Pharmacokinetics and Pharmacodynamics of Proton Pump Inhibitors
    Mazer-Amirshahi, Maryann
    van den Anker, John
    JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 53 (03): : 359 - 359
  • [4] CYP2C19 polymorphism and proton pump inhibitors (PPI) in Helicobacter pylori eradication therapy - A metaanalysis
    Treiber, GG
    Schwab, M
    Klotz, U
    GASTROENTEROLOGY, 2004, 126 (04) : A603 - A603
  • [5] Influence of CYP2C19 functional polymorphism on Helicobacter pylori eradication
    Ozdil, Burhan
    Akkiz, Hikmet
    Bayram, Suleyman
    Bekar, Aynur
    Akgollu, Ersin
    Sandikci, Macit
    TURKISH JOURNAL OF GASTROENTEROLOGY, 2010, 21 (01): : 23 - 28
  • [6] Reply to: Letter to the Editor "Impact of the CYP2C19*17 Polymorphism on the Pharmacokinetics and Pharmacodynamics of Proton Pump Inhibitors"
    Jiang, Fen
    Shin, Jae-Gook
    JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 53 (03): : 360 - 360
  • [7] Should the presence of polymorphisms of CYP2C19 enzymes influence the choice of the proton pump inhibitor for treatment of Helicobacter pylori infection?
    van Zanten, Sander Veldhuyzen
    Thompson, Kara
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2006, 101 (07): : 1476 - 1478
  • [8] Can Helicobacter pylori be eradicated with high-dose proton pump inhibitor in extensive metabolizers with the CYP2C19 genotypic polymorphism?
    Ormeci, A.
    Emrence, Z.
    Baran, B.
    Soyer, O. M.
    Gokturk, S.
    Evirgen, S.
    Akyuz, F.
    Karaca, C.
    Besisik, F.
    Kaymakoglu, S.
    Ustek, D.
    Demir, K.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2016, 20 (09) : 1795 - 1797
  • [9] Clinical impact of CYP2C19 polymorphism on pharmacokinetics and pharmacodynamics of proton pump inhibitors (PPIs): from evidence to interpretation
    Fukushima, Y
    Nakagawa, K
    Moriyama, Y
    Sakurai, M
    Yamasaki, S
    Ieiri, I
    Otsubo, K
    Furuta, T
    Shirai, N
    Hanai, H
    Ohashi, K
    Sakurai, K
    Tomita, K
    Matsushita, K
    Ishizaki, T
    JAPANESE JOURNAL OF PHARMACOLOGY, 2002, 88 : 281P - 281P
  • [10] Effects of CYP2C19 genetic polymorphism on the pharmacokinetics and pharmacodynamics of omeprazole in Chinese people
    Hu, Xiang-Peng
    Xu, Jian-Ming
    Hu, Yong-Mei
    Mei, Qiao
    Xu, Xin-Hua
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2007, 32 (05) : 517 - 524
12345